▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
The Interaction Finder allows you to easily search for drug interactions by active substance name or keywords.
Paxlovid contains nirmatrelvir and ritonavir. Ritonavir is administered with nirmatrelvir as a pharmacokinetic enhancer to increase systemic concentrations1
Ritonavir is a widely used treatment with a known profile2,3
- Ritonavir is used in combination with other antivirals to similarly inhibit drug metabolism2,3
For a list of potential clinically significant drug interactions, including contraindicated drugs, refer to Section 4.3: Contraindications, Section 4.5: Interaction with other medicinal products and other forms of interaction and Table 1: Interaction with other medicinal products and other forms of interaction of the SmPC [here].1
Discover the efficacy data and trial design of EPIC-HR.
1. PAXLOVID Summary of Product Characteristics.
2. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593.
3. NORVIR Summary of Product Characteristics.
ABBREVIATED PRESCRIBING INFORMATION – IRELAND
Paxlovid®▼(nirmatrelvir/ritonavir) 150 mg + 100 mg film-coated tablets
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Please refer to the Summary of Product Characteristics (SmPC) before prescribing Paxlovid.
Indications: Treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID 19 (see section 5.1 of the SmPC). Presentation: Each pink film-coated tablet contains 150 mg of nirmatrelvir. Each white film‑coated tablet contains 100 mg of ritonavir. Dosage: The recommended dosage is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) all taken together orally every 12 hours for 5 days. Paxlovid should be administered as soon as possible after a diagnosis of COVID-19 and within 5 days of symptom onset. Completion of the full 5-day treatment course is recommended even if the patient requires hospitalisation due to severe or critical COVID-19. In patients with moderate renal impairment, (eGFR ≥ 30 to < 60 mL/min) the dose of Paxlovid should be reduced to nirmatrelvir/ritonavir 150 mg/100 mg every 12 hours for 5 days. Paxlovid should not be used in patients with severe renal or severe (Child-Pugh Class C) hepatic impairment. Contraindications: Hypersensitivity to the active substances or to any of the excipients. Medicinal products listed below are a guide and not considered a comprehensive list of all possible medicinal products that are contraindicated with Paxlovid. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions: Alpha1‑adrenoreceptor antagonist: alfuzosin; Antianginal: ranolazine; Antiarrhythmics: dronedarone, propafenone, quinidine; Anticancer drugs: neratinib, venetoclax; Anti-gout: colchicine; Antihistamines: terfenadine; Antipsychotics/Neuroleptics: lurasidone, pimozide, quetiapine; Benign prostatic hyperplasia medicinal products: silodosin; Cardiovascular medicinal products: eplerenone, ivabradine; Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine; GI motility agent: cisapride; Immunosuppressants: voclosporin; Lipid-modifying agents: lovastatin, simvastatin, lomitapide; Migraine medicinal products: eletriptan; Mineralocorticoid receptor antagonists: finerenone; Opioid antagonists: naloxegol; PDE5 inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Sedative/Hypnotics: clorazepate, diazepam, estazolam, flurazepam, oral midazolam, triazolam; Vasopressin receptor antagonists: tolvaptan. Medicinal products that are potent CYP3A inducers where significantly reduced nirmatrelvir/ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance: Antibiotics: rifampicin, rifapentine; Anticancer drugs: apalutamide; Anticonvulsants: carbamazepine, phenobarbital, phenytoin, primidone; Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor; Herbal products: St. John’s wort (Hypericum perforatum). Warnings and Precautions: Risk of serious adverse reactions due to interactions with other medicinal products: Due to effects on CYP3A metabolic pathways, potential for drug-drug interactions (DDIs) should be considered with other medicinal products prior to and during Paxlovid therapy; concomitant medicinal products should be reviewed during Paxlovid therapy and the patient should be monitored for the adverse reactions associated with the concomitant medicinal products. In certain patients, a multi-disciplinary approach (e.g., involving physicians and specialists in clinical pharmacology) should be considered for management of DDIs especially if concomitant medications are withheld, their dosage is reduced, or if monitoring of side effects is necessary. The risk of interactions with concomitant medications during the 5-day treatment period for Paxlovid should be weighed against the risk of not receiving Paxlovid; please refer to Table 1 in SmPC section 4.5. Coadministration with calcineurin inhibitors and mTOR inhibitors: Consultation of a multidisciplinary group (e.g., involving physicians, specialists in immunosuppressive therapy, and/or specialists in clinical pharmacology) is required to handle the complexity of this coadministration by closely and regularly monitoring immunosuppressant serum concentrations and adjusting the dose of the immunosuppressant in accordance with the latest guidelines (see SmPC section 4.5). Hypersensitivity reactions: If signs and symptoms of a clinically significant hypersensitivity reaction, serious skin reaction (including Toxic Epidermal Necrolysis and Stevens-Johnson syndrome) or anaphylaxis occur, immediately discontinue Paxlovid and initiate appropriate medications and/or supportive care. Severe renal impairment: Paxlovid should not be used in patients with severe renal impairment (eGFR < 30 mL/min, including patients with ESRD under haemodialysis). Severe hepatic impairment: Paxlovid should not be used in patients with severe hepatic impairment. Hepatotoxicity: Caution should be exercised when administering Paxlovid to patients with pre‑existing liver diseases, liver enzyme abnormalities or hepatitis. Elevation in blood pressure: Specific attention including regular monitoring of blood pressure should be paid notably to elderly patients since they are at higher risk of experiencing serious complications of hypertension. HIV resistance: As nirmatrelvir is coadministered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. Excipients: nirmatrelvir tablets contain lactose, patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicine. Contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'. Drug Interactions: Nirmatrelvir and ritonavir are CYP3A substrates. Coadministration of Paxlovid with medicinal products that induce CYP3A may decrease nirmatrelvir and ritonavir plasma concentrations and reduce Paxlovid therapeutic effect. Coadministration of Paxlovid with medicinal product that inhibits CYP3A4 may increase nirmatrelvir and ritonavir plasma concentrations. Paxlovid (nirmatrelvir/ritonavir) is a strong inhibitor of CYP3A and increases plasma concentrations of medicinal products that are primarily metabolised by CYP3A. Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the following ranked order: CYP3A4 > CYP2D6. Coadministration of Paxlovid with drug substrates of CYP2D6 may increase the CYP2D6 substrate concentration. Paxlovid also has a high affinity for P‑glycoprotein (P‑gp) and inhibits this transporter; caution should thus be exercised in case of concomitant treatment. Close drug monitoring for safety and efficacy should be performed, and dose reduction may be adjusted accordingly, or avoid concomitant use. Paxlovid may induce glucuronidation and oxidation by CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 thereby increasing the biotransformation of some medicinal products metabolised by these pathways. Based on in vitro studies there is a potential for nirmatrelvir to inhibit MDR1 and OATP1B1 at clinically relevant concentrations. Dedicated drug-drug interactions studies conducted with Paxlovid indicate that the drug interactions are primarily due to ritonavir. Hence, drug interactions pertaining to ritonavir are applicable for Paxlovid. Medicinal products listed here are a guide and not considered a comprehensive list of all possible medicinal products that may interact with nirmatrelvir/ritonavir: Alpha1‑adrenoreceptor antagonist: tamsulosin; Amphetamine derivatives: amphetamine; Analgesics: buprenorphine, fentanyl, oxycodone, methadone, morphine, pethidine, piroxicam; Antiarrhythmics: amiodarone, flecainide, digoxin, disopyramide; Antiasthmatic: theophylline; Anticancer: abemaciclib, afatinib, ceritinib, dasatinib, nilotinib, vinblastine, vincristine, encorafenib, ivosidenib, fostamatinib, ibrutinib, venetoclax (contraindicated in some circumstances); Anticoagulants: apixaban, dabigatran, rivaroxaban, warfarin; Anticonvulsants: clonazepam, divalproex, lamotrigine; Anticorticosteroids: ketoconazole; Antidepressants: amitriptyline, fluoxetine, imipramine, nortriptyline, paroxetine, sertraline; Anti-HCV: glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir; Antihistamines: fexofenadine, loratadine; Anti-HIV: bictegravir/emtricitabine/tenofovir, efavirenz, maraviroc, raltegravir, zidovudine; Anti-infectives: atovaquone, bedaquiline, clarithromycin, delamanid, erythromycin, itraconazole, fusidic acid (systemic route), rifabutin, sulfamethoxazole/trimethoprim, voriconazole; Antipsychotics: clozapine, haloperidol, risperidone, thioridazine; β2-agonist (long acting): salmeterol; Calcium channel antagonists: amlodipine, diltiazem, felodipine, nicardipine, nifedipine, verapamil, lercanidipine; Cardiovascular agents: aliskiren, cilostazol, clopidogrel, ticagrelor; Cystic fibrosis transmembrane conductance regulator potentiators: elexacaftor/ tezacaftor/ivacaftor, ivacaftor, tezacaftor/ivacaftor; Dipeptidyl peptidase 4 (DPP4) inhibitors: saxagliptin; Endothelin antagonists: bosentan, riociguat; HMG Co-A reductase: atorvastatin, fluvastatin, pravastatin, rosuvastatin; Hormonal contraceptive: ethinyl estradiol; Immunosuppressants: cyclosporine, tacrolimus, everolimus, sirolimus; Janus kinase (JAK) inhibitors: tofacitinib, upadacitinib; Migraine medicinal products: rimegepant; Muscarinic receptor antagonists: darifenacin, solifenacine; Neuropsychiatric agents: aripiprazole, brexpiprazole, cariprazine; Sedatives/Hypnotics: alprazolam, buspirone, parenteral midazolam; Sleeping agent: zolpidem; Smoke cessation: buproprion; Steroids: budesonide, inhaled, injectable or intranasal fluticasone propionate, triamcinolone, dexamethasone, prednisolone; Thyroid hormone replacement therapy: levothyroxine. Please refer to Table 1 in SmPC section 4.5 for additional information on interaction with medicinal products / other forms of interaction. Fertility, pregnancy and lactation: Women of childbearing potential should avoid becoming pregnant during treatment with Paxlovid and as a precautionary measure for 7 days after completing Paxlovid. Patients using combined hormonal contraceptives should be advised to use an effective alternative contraceptive method or an additional barrier method of contraception during treatment and until after one complete menstrual cycle after stopping Paxlovid. Paxlovid is not recommended during pregnancy and in women of childbearing potential not using contraception unless the clinical condition requires treatment with Paxlovid. Breast feeding should be discontinued during treatment with Paxlovid and as a precautionary measure for 7 days after completing Paxlovid. Driving and operating machinery: Paxlovid is expected to have no influence on the ability to drive and use machines. Undesirable effects: The safety profile of the product is based on adverse reactions reported in clinical trials and spontaneous reporting. Common (≥ 1/100 to < 1/10) adverse events reported were dysgeusia, headache, diarrhoea, vomiting and nausea. Uncommon (≥ 1/1000 to < 1/100) adverse events reported were hypersensitivity, rash, hypertension, abdominal pain and myalgia. Rare (≥ 1/10,000 to < 1/1000) adverse events reported were anaphylaxis, toxic epidermal necrolysis, Stevens‑Johnson syndrome, pruritus and malaise. See SmPC section 4.8 for full details.
Legal Category: S1A. Package Quantities: 150 mg + 100 mg, 20 + 10 film‑coated tablets. Marketing Authorisation Number: EU/1/22/1625/001. Marketing Authorisation Holder: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brussels, Belgium. For further information on this medicine please contact: Pfizer Medical Information on 1800 633 363 or at [email protected]. For queries regarding product availability please contact: Pfizer Healthcare Ireland, Pfizer Building 9, Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24 + 353 1 4676500.
Last revised: 12/2023
Ref: PX 12_0
Paxlovid®▼(nirmatrelvir/ritonavir) 150 mg + 100 mg film-coated tablets
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.Please refer to the Summary of Product Characteristics (SmPC) before prescribing Paxlovid.
Indications: Treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID 19 (see section 5.1 of the SmPC). Presentation: Each pink film-coated tablet contains 150 mg of nirmatrelvir. Each white film‑coated tablet contains 100 mg of ritonavir. Dosage: The recommended dosage is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) all taken together orally every 12 hours for 5 days. Paxlovid should be administered as soon as possible after a diagnosis of COVID-19 and within 5 days of symptom onset. Completion of the full 5-day treatment course is recommended even if the patient requires hospitalisation due to severe or critical COVID-19. In patients with moderate renal impairment, (eGFR ≥ 30 to < 60 mL/min) the dose of Paxlovid should be reduced to nirmatrelvir/ritonavir 150 mg/100 mg every 12 hours for 5 days. Paxlovid should not be used in patients with severe renal or severe (Child-Pugh Class C) hepatic impairment. Contraindications: Hypersensitivity to the active substances or to any of the excipients. Medicinal products listed below are a guide and not considered a comprehensive list of all possible medicinal products that are contraindicated with Paxlovid. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions: Alpha1‑adrenoreceptor antagonist: alfuzosin; Antianginal: ranolazine; Antiarrhythmics: dronedarone, propafenone, quinidine; Anticancer drugs: neratinib, venetoclax; Anti-gout: colchicine; Antihistamines: terfenadine; Antipsychotics/Neuroleptics: lurasidone, pimozide, quetiapine; Benign prostatic hyperplasia medicinal products: silodosin; Cardiovascular medicinal products: eplerenone, ivabradine; Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine; GI motility agent: cisapride; Immunosuppressants: voclosporin; Lipid-modifying agents: lovastatin, simvastatin, lomitapide; Migraine medicinal products: eletriptan; Mineralocorticoid receptor antagonists: finerenone; Opioid antagonists: naloxegol; PDE5 inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Sedative/Hypnotics: clorazepate, diazepam, estazolam, flurazepam, oral midazolam, triazolam; Vasopressin receptor antagonists: tolvaptan. Medicinal products that are potent CYP3A inducers where significantly reduced nirmatrelvir/ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance: Antibiotics: rifampicin, rifapentine; Anticancer drugs: apalutamide; Anticonvulsants: carbamazepine, phenobarbital, phenytoin, primidone; Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor; Herbal products: St. John’s wort (Hypericum perforatum). Warnings and Precautions: Risk of serious adverse reactions due to interactions with other medicinal products: Due to effects on CYP3A metabolic pathways, potential for drug-drug interactions (DDIs) should be considered with other medicinal products prior to and during Paxlovid therapy; concomitant medicinal products should be reviewed during Paxlovid therapy and the patient should be monitored for the adverse reactions associated with the concomitant medicinal products. In certain patients, a multi-disciplinary approach (e.g., involving physicians and specialists in clinical pharmacology) should be considered for management of DDIs especially if concomitant medications are withheld, their dosage is reduced, or if monitoring of side effects is necessary. The risk of interactions with concomitant medications during the 5-day treatment period for Paxlovid should be weighed against the risk of not receiving Paxlovid; please refer to Table 1 in SmPC section 4.5. Coadministration with calcineurin inhibitors and mTOR inhibitors: Consultation of a multidisciplinary group (e.g., involving physicians, specialists in immunosuppressive therapy, and/or specialists in clinical pharmacology) is required to handle the complexity of this coadministration by closely and regularly monitoring immunosuppressant serum concentrations and adjusting the dose of the immunosuppressant in accordance with the latest guidelines (see SmPC section 4.5). Hypersensitivity reactions: If signs and symptoms of a clinically significant hypersensitivity reaction, serious skin reaction (including Toxic Epidermal Necrolysis and Stevens-Johnson syndrome) or anaphylaxis occur, immediately discontinue Paxlovid and initiate appropriate medications and/or supportive care. Severe renal impairment: Paxlovid should not be used in patients with severe renal impairment (eGFR < 30 mL/min, including patients with ESRD under haemodialysis). Severe hepatic impairment: Paxlovid should not be used in patients with severe hepatic impairment. Hepatotoxicity: Caution should be exercised when administering Paxlovid to patients with pre‑existing liver diseases, liver enzyme abnormalities or hepatitis. Elevation in blood pressure: Specific attention including regular monitoring of blood pressure should be paid notably to elderly patients since they are at higher risk of experiencing serious complications of hypertension. HIV resistance: As nirmatrelvir is coadministered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. Excipients: nirmatrelvir tablets contain lactose, patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicine. Contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'. Drug Interactions: Nirmatrelvir and ritonavir are CYP3A substrates. Coadministration of Paxlovid with medicinal products that induce CYP3A may decrease nirmatrelvir and ritonavir plasma concentrations and reduce Paxlovid therapeutic effect. Coadministration of Paxlovid with medicinal product that inhibits CYP3A4 may increase nirmatrelvir and ritonavir plasma concentrations. Paxlovid (nirmatrelvir/ritonavir) is a strong inhibitor of CYP3A and increases plasma concentrations of medicinal products that are primarily metabolised by CYP3A. Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the following ranked order: CYP3A4 > CYP2D6. Coadministration of Paxlovid with drug substrates of CYP2D6 may increase the CYP2D6 substrate concentration. Paxlovid also has a high affinity for P‑glycoprotein (P‑gp) and inhibits this transporter; caution should thus be exercised in case of concomitant treatment. Close drug monitoring for safety and efficacy should be performed, and dose reduction may be adjusted accordingly, or avoid concomitant use. Paxlovid may induce glucuronidation and oxidation by CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 thereby increasing the biotransformation of some medicinal products metabolised by these pathways. Based on in vitro studies there is a potential for nirmatrelvir to inhibit MDR1 and OATP1B1 at clinically relevant concentrations. Dedicated drug-drug interactions studies conducted with Paxlovid indicate that the drug interactions are primarily due to ritonavir. Hence, drug interactions pertaining to ritonavir are applicable for Paxlovid. Medicinal products listed here are a guide and not considered a comprehensive list of all possible medicinal products that may interact with nirmatrelvir/ritonavir: Alpha1‑adrenoreceptor antagonist: tamsulosin; Amphetamine derivatives: amphetamine; Analgesics: buprenorphine, fentanyl, oxycodone, methadone, morphine, pethidine, piroxicam; Antiarrhythmics: amiodarone, flecainide, digoxin, disopyramide; Antiasthmatic: theophylline; Anticancer: abemaciclib, afatinib, ceritinib, dasatinib, nilotinib, vinblastine, vincristine, encorafenib, ivosidenib, fostamatinib, ibrutinib, venetoclax (contraindicated in some circumstances); Anticoagulants: apixaban, dabigatran, rivaroxaban, warfarin; Anticonvulsants: clonazepam, divalproex, lamotrigine; Anticorticosteroids: ketoconazole; Antidepressants: amitriptyline, fluoxetine, imipramine, nortriptyline, paroxetine, sertraline; Anti-HCV: glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir; Antihistamines: fexofenadine, loratadine; Anti-HIV: bictegravir/emtricitabine/tenofovir, efavirenz, maraviroc, raltegravir, zidovudine; Anti-infectives: atovaquone, bedaquiline, clarithromycin, delamanid, erythromycin, itraconazole, fusidic acid (systemic route), rifabutin, sulfamethoxazole/trimethoprim, voriconazole; Antipsychotics: clozapine, haloperidol, risperidone, thioridazine; β2-agonist (long acting): salmeterol; Calcium channel antagonists: amlodipine, diltiazem, felodipine, nicardipine, nifedipine, verapamil, lercanidipine; Cardiovascular agents: aliskiren, cilostazol, clopidogrel, ticagrelor; Cystic fibrosis transmembrane conductance regulator potentiators: elexacaftor/ tezacaftor/ivacaftor, ivacaftor, tezacaftor/ivacaftor; Dipeptidyl peptidase 4 (DPP4) inhibitors: saxagliptin; Endothelin antagonists: bosentan, riociguat; HMG Co-A reductase: atorvastatin, fluvastatin, pravastatin, rosuvastatin; Hormonal contraceptive: ethinyl estradiol; Immunosuppressants: cyclosporine, tacrolimus, everolimus, sirolimus; Janus kinase (JAK) inhibitors: tofacitinib, upadacitinib; Migraine medicinal products: rimegepant; Muscarinic receptor antagonists: darifenacin, solifenacine; Neuropsychiatric agents: aripiprazole, brexpiprazole, cariprazine; Sedatives/Hypnotics: alprazolam, buspirone, parenteral midazolam; Sleeping agent: zolpidem; Smoke cessation: buproprion; Steroids: budesonide, inhaled, injectable or intranasal fluticasone propionate, triamcinolone, dexamethasone, prednisolone; Thyroid hormone replacement therapy: levothyroxine. Please refer to Table 1 in SmPC section 4.5 for additional information on interaction with medicinal products / other forms of interaction. Fertility, pregnancy and lactation: Women of childbearing potential should avoid becoming pregnant during treatment with Paxlovid and as a precautionary measure for 7 days after completing Paxlovid. Patients using combined hormonal contraceptives should be advised to use an effective alternative contraceptive method or an additional barrier method of contraception during treatment and until after one complete menstrual cycle after stopping Paxlovid. Paxlovid is not recommended during pregnancy and in women of childbearing potential not using contraception unless the clinical condition requires treatment with Paxlovid. Breast feeding should be discontinued during treatment with Paxlovid and as a precautionary measure for 7 days after completing Paxlovid. Driving and operating machinery: Paxlovid is expected to have no influence on the ability to drive and use machines. Undesirable effects: The safety profile of the product is based on adverse reactions reported in clinical trials and spontaneous reporting. Common (≥ 1/100 to < 1/10) adverse events reported were dysgeusia, headache, diarrhoea, vomiting and nausea. Uncommon (≥ 1/1000 to < 1/100) adverse events reported were hypersensitivity, rash, hypertension, abdominal pain and myalgia. Rare (≥ 1/10,000 to < 1/1000) adverse events reported were anaphylaxis, toxic epidermal necrolysis, Stevens‑Johnson syndrome, pruritus and malaise. See SmPC section 4.8 for full details.
Legal Category: S1A. Package Quantities: 150 mg + 100 mg, 20 + 10 film‑coated tablets. Marketing Authorisation Number: EU/1/22/1625/001. Marketing Authorisation Holder: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brussels, Belgium. For further information on this medicine please contact: Pfizer Medical Information on 1800 633 363 or at [email protected]. For queries regarding product availability please contact: Pfizer Healthcare Ireland, Pfizer Building 9, Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24 + 353 1 4676500.
Last revised: 12/2023
Ref: PX 12_0
Legal Category: S1A
Further information is available upon request
PP-C1D-IRL-0041. June 2024.
The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.
I confirm that I am a healthcare professional* resident in the Republic of Ireland.
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.
*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses
Terms of use
PP-UNP-IRL-0832. October 2024
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
PP-UNP-IRL-0832. October 2024
PP-UNP-IRL-0832. October 2024